Abstract

The invention relates to a recombinant parasporin 2 protein comprising one heterologous protease cleavage site to allow the removal of the N-terminal sequence that inhibits the pore-forming ability and, optionally, a further heterologous protease cleavage site to allow the removal of the C-terminal sequence that inhibits the pore-forming ability, and to the medical uses there

IPC Classes  ?

• A61K 38/00 - Medicinal preparations containing peptides
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C12N 15/86 - Viral vectors

Abstract

The present invention relates to oncolytic viruses with controlled replication which can be incorporated into carrier cells for cancer therapy.

IPC Classes  ?

• A61K 35/761 - Adenovirus

Abstract

The invention relates to an oligomer comprising at least three polypeptides, wherein each polypeptide comprises the CCP6 domain of the C4BP alpha chain or a functionally equivalent variant thereof and an oligomerization domain, and wherein said oligomer does not comprise the C4BP beta chain, for use in the prevention and/or treatment of a disease involving an undesired activation of the immune system in a subject having CD36 expression on the surface of the monocytes/macrophages.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 37/00 - Drugs for immunological or allergic disorders
• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals

Goods & Services

Computer software for the display of digital media; Artificial intelligence software for analysis; Software for processing images, graphics and text; Data compression software; Science software.

Goods & Services

Software; Computer software platforms; Machine learning software; Computer search engine software; Software for searching and retrieving information across a computer network; Data compression software; Science software; Artificial intelligence software for analysis.

Goods & Services

Software; Machine learning software for finance; Computer search engine software; Software for searching and retrieving information across a computer network; Data compression software; Science software; Artificial intelligence software for analysis.

Abstract

The invention is related to an oncolytic adenovirus that comprises a sequence encoding a hyaluronidase enzyme inserted in its genome. This adenovirus spreads more efficiently in the tumour mass and therefore the oncolytic effect is increased. Injecting the oncolytic adenovirus of the invention endovenously, tumour volume regressions are obtained. Therefore the oncolytic adenovirus of the present invention is useful for the treatment of a cancer or a pre-malignant state of cancer.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• A61K 35/761 - Adenovirus
• A61K 38/00 - Medicinal preparations containing peptides
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12N 9/26 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on alpha-1, 4-glucosidic bonds, e.g. hyaluronidase, invertase, amylase
• C12N 15/86 - Viral vectors

Abstract

The invention relates to compounds based on a recombinant form of the CCP6 region of C4BP and an oligomerization domain for use in the prevention and/or treatment of immunological diseases. Moreover, the invention relates to methods for obtaining tolerogenic dendritic cells and tolerogenic macrophages using the compounds of the invention and to the cells obtained by these methods and their therapeutic uses.

IPC Classes  ?

• A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 5/0784 - Dendritic cellsProgenitors thereof

Abstract

The present invention corresponds to the field of cancer and is related to predicting cancer detection, diagnosis, monitoring and prediction of response to treatment, in particular platelet derived-endothelial cell growth factor (PD-ECGF) levels for their use as a potential value in monitoring disease evolution and predicting response to anti-angiogenic treatment.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

Compounds derived from ursodeoxycholic acid of formula (I) and to methods for obtaining same, as well as the use thereof in the treatment of polycystic diseases, particularly autosomal dominant polycystic liver disease, autosomal dominant polycystic kidney disease, or autosomal recessive polycystic kidney disease.

IPC Classes  ?

• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol

Abstract

The invention relates to a recombinant adenovirus comprising an albumin-binding moiety on the outer surface of the adenoviral hexon protein, pharmaceutical compositions containing it and its medical use. Particularly, the invention relates to an oncolytic adenovirus comprising a sequence encoding an albumin-binding moiety inserted in the hypervariable region 1 (HVR1) of the hexon protein coding sequence and its use in the prevention and/or treatment of cancer.

IPC Classes  ?

• C07K 14/315 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C07K 14/075 - Adenoviridae
• A61K 35/761 - Adenovirus
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses

Abstract

The invention relates to in vitro methods for detecting bacteremia, for selecting a therapy for a subject with cystic fibrosis or for a subject with systemic inflammatory response syndrome and for selecting a subject with cystic fibrosis or with systemic inflammatory syndrome for a particular therapy based on the expression levels of a gene selected from tumor necrosis factor alpha (TNFα), IL-1b, IL-10, CCL2, interferon beta (IFN-β), IL-17, IL-2, IL-4 and VEGF in a blood sample from the subject. The invention also relates to a kit comprising a TLR-4 agonist and a reagent specific for determining the level of at least one cytokine selected from the group consisting of tumor necrosis factor alpha (TNFα), IL-1b, IL-10, CCL2, interferon beta (IFN-β), IL-17, IL-2, IL-4 and VEGF and to the uses of this kit.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

It relates to a compound of formula (I), particularly asenapine, or a pharmaceutically acceptable salt thereof, or any stereoisomer or mixtures of stereoisomers, either of the compound of formula (I) or of any of its pharmaceutically acceptable salts, for use in the treatment and/or prevention of cancer. It also relates to a drug combination of a compound of formula (I), its stereoisomers and/or salts thereof, and one or more anticancer agents selected from the group consisting of chemotherapy agents, immunotherapy agents, and hormone therapy agents; and to pharmaceutical compositions and to a kit of parts comprising this combination, as well as the use of the drug combination, the compositions, or kit of parts for use in the treatment and/or prevention of cancer.

IPC Classes  ?

• A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
• A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• A61K 33/243 - PlatinumCompounds thereof
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• A61P 35/04 - Antineoplastic agents specific for metastasis

Abstract

The present invention provides S-methyl-L-ergothioneine for use in diagnosis and/or prognosis. The invention also provides a method for the diagnosis and/or prognosis of a renal disease comprising the step of determining the amount of S-methyl-L-ergothioneine in an isolated test sample of a subject, and methods for deciding or recommending whether to initiate a therapeutic intervention or for determining the efficacy of a therapeutic intervention. It is also herein provided ergothioneine for use in the treatment and/or prevention of a renal lithiasis or an aminoaciduria, and ergothioneine for use in combination therapy.

IPC Classes  ?

• A61K 31/4172 - Imidazole-alkanecarboxylic acids, e.g. histidine
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• A61K 31/223 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-amino acids
• A61K 31/16 - Amides, e.g. hydroxamic acids
• A61P 13/04 - Drugs for disorders of the urinary system for urolithiasis

Abstract

The present invention belongs to the field of genetic therapy. In particular, the invention refers to EphA2 specific RNA-based constructs, which are useful for the treatment, prevention and diagnosis of EphA2 expressing cancers.

IPC Classes  ?

• C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 35/00 - Antineoplastic agents
• A61P 35/04 - Antineoplastic agents specific for metastasis

Abstract

The present invention provides a compound comprising a fusion polypeptide of formula (I): R1-L-R2-Fc wherein R1, which is at the N-terminal end of the polypeptide, is PD-L2 or a PD1-binding fragment thereof, L is a peptide linker, R2 is CTLA-4 or a CD80/CD86-binding fragment thereof, and Fc, which is at the C-terminal end of the polypeptide, is an immunoglobulin Fc domain. The present invention also provides a dimer of the compound, a polynucleotide which encodes the polypeptide, a vector comprising the polynucleotide, a host cell which contains the polynucleotide, a composition and a kit comprising the compound. The invention also provides the compound or the dimer for use in therapy, diagnosis and prognosis, in particular for the treatment of autoimmune diseases or transplant rejection.

IPC Classes  ?

• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C12N 15/62 - DNA sequences coding for fusion proteins

Abstract

A composition is for improving the culture and implantation of mammalian embryos. The composition includes one or more of the fractions of human plasma fractionation using the Cohn method wherein in the composition human serum albumin (HSA) is between 90% and 96% of the total proteins in the composition, alfa and beta globulins are between 3.5% and 9.99% of the total proteins in the composition, and gamma globulin is between 0.01% and 0.5% of the total proteins in the composition.

IPC Classes  ?

• C12N 5/073 - Embryonic cells or tissuesFoetal cells or tissues

Abstract

The present invention relates to an in vitro method to diagnose or determine the risk of developing a neurodegenerative disease in a subject based on the determination of the methylation pattern in certain regions of mitochondrial DNA from the subject. Finally, the present invention relates to nucleic acids suitable for application of the invention.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

SIGLEC17P AP4S1, ZMYM6, USP21, DMAP1, SUPT5H, TP53BP1, NECAB3, BTD, DACT1SIGLEC17P SIGLEC17P and/or of at least one of its associated downstream coding genes is higher than a reference value, this is indicative of renal allograft antibody-mediated rejection.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates to methods useful for predicting the risk of local invasion and/or metastasis induced by an antiangiogenic treatment in a patient who suffers from cancer, or for predicting the response to an antiangiogenic therapy, wherein the methods comprise the determination of the expression level of ALDH1A3, as well as methods for providing personalized medicine to said patients. These methods can be used to identify those patients who are at a high risk of local invasion and/or metastasis. The identification of this subgroup of patients may guide the selection of therapies, improving financial and health outcomes. The invention relates as well to the use of reagents for carrying out the predictive methods.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

Presented are methods of assessing a deficit in DNA damage repair capability in cancer cells. Cancer cells having this DNA damage repair phenotype have increased susceptibility to certain treatments, including genotoxic treatments, treatment with PARP1 inhibitors, and immunotherapies. The methods encompass the use of novel gene expression signatures that enable facile and rapid determination of the DNA damage repair phenotype in cancer cells of a sample. By these methods, subjects having cancer that is amenable to genotoxic treatment, PARP1 inhibition, or immunotherapy may be identified and administered a suitable treatment. Also disclosed is a method of inducing the DNA damage repair deficit phenotype in cancer cells to sensitize them to various treatments.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/6834 - Enzymatic or biochemical coupling of nucleic acids to a solid phase
• A61K 33/243 - PlatinumCompounds thereof
• A61P 41/00 - Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
• A61K 31/502 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy

Abstract

The invention relates to in vitro methods for detecting bacteremia, for selecting a therapy for a subject with cystic fibrosis or for a subject with systemic inflammatory response syndrome and for selecting a subject with cystic fibrosis or with systemic inflammatory syndrome for a particular therapy based on the expression levels of a gene selected from 5 tumor necrosis factor alpha (TNFα), IL-1b, IL-10, CCL2, interferon beta (IFN-β), IL-17, IL-2, IL-4 and VEGF in a blood sample from the subject. The invention also relates to a kit comprising a TLR-4 agonist and a reagent specific for determining the level of at least one cytokine selected from the group consisting of tumor necrosis factor alpha (TNFα), IL-1b, IL-10, CCL2, interferon beta (IFN-β), IL-17, IL-2, IL-4 and VEGF and to the uses 10 of this kit.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

in vitro in vitro method and kits for the prognosis of amyotrophic lateral sclerosis (ALS), based on the expression or activity of ELOVL6 ( Elongation of Very Long chain fatty acids protein 6).

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to compounds derived from ursodeoxycholic acid of formula (I), to methods for obtaining same, as well as the use thereof in the treatment of polycystic diseases, particularly autosomal dominant polycystic liver disease, autosomal dominant polycystic kidney disease, or autosomal recessive polycystic kidney disease.

IPC Classes  ?

• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol

Abstract

The invention relates to compounds based on a recombinant form of the CCP6 region of C4BP and an oligomerization domain for use in the prevention and/or treatment of immunological diseases. Moreover, the invention relates to methods for obtaining tolerogenic dendritic cells and tolerogenic macrophages using the compounds of the invention and to the cells obtained by these methods and their therapeutic uses.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans

Abstract

The present invention provides S-methyl-L-ergothioneine for use in diagnosis and/or prognosis. The invention also provides a method for the diagnosis and/or prognosis of a renal disease comprising the step of determining the amount of S-methyl-L-ergothioneine in an isolated test sample of a subject, and methods for deciding or recommending whether to initiate a therapeutic intervention or for determining the efficacy of a therapeutic intervention. It is also herein provided ergothioneine for use in the treatment and/or prevention of a renal lithiasis or an aminoaciduria, and ergothioneine for use in combination therapy.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates to methods for selecting a restrictive or a malabsorptive bariatric surgical procedure for a patient in need thereof, wherein the method comprises determining the circulating succinate level in a biofluid sample from said patient. These methods can be used to identify those subgroups of patients who are more likely to benefit from a restrictive or a malabsorptive bariatric surgical procedure, thereby improving financial and health outcomes. The invention also relates to methods for predicting, before bariatric surgery, type 2 diabetes remission after restrictive bariatric surgery in a patient suffering from type 2 diabetes. Finally, the invention relates to uses of circulating succinate levels as an effective predictive factor for selecting a bariatric surgical procedure for a patient, as well as an informative biomarker for predicting, before bariatric surgery, type 2 diabetes remission after restrictive bariatric surgery in a patient suffering from type 2 diabetes.

IPC Classes  ?

• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

The present invention belongs to the field of genetic therapy. In particular, the invention refers to EphA2 specific RNA-based constructs, which are useful for the treatment, prevention and diagnosis of EphA2 expressing cancers.

IPC Classes  ?

• C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present invention relates to the implantation of mammalian embryos using a composition which comprise one or more of the fractions of human plasma fractionation using the Cohn method wherein in said composition human serum albumin (HSA) is between 90 % and 96 % of the total proteins in the composition, alfa and beta globulins are between 3.5 % and 9.99 % of the total proteins in the composition, and gamma globulin is between 0.01 % and 0.5 % of the total proteins in the composition. In addition, the present invention relates to the preparation method and use of said composition in the culture of mammalian embryos.

IPC Classes  ?

• C12N 5/073 - Embryonic cells or tissuesFoetal cells or tissues

Abstract

The present invention provides a compound comprising a fusion polypeptide of formula (I): R1-L-R2-Fc wherein R1, which is at the N-terminal end of the polypeptide, is PD-L2 or a PD1- binding fragment thereof, L is a peptide linker, R2 is CTLA-4 or a CD80/CD86-binding fragment thereof, and Fc, which is at the C-terminal end of the polypeptide,is an immunoglobulin Fc domain.The present invention also provides a dimer of the compound, a polynucleotide which encodes the polypeptide, a vector comprising the polynucleotide, a host cell which contains the polynucleotide, a composition and a kit comprising the compound. The invention also provides the compound or the dimer for use in therapy, diagnosis and prognosis,in particular for the treatment of autoimmune diseases or transplant rejection.

IPC Classes  ?

• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C12N 15/62 - DNA sequences coding for fusion proteins

Abstract

2. Pharmaceutical compositions comprising from 0.45 mg to 18.90 mg of these compounds for the prevention and/or treatment of these diseases are also described.

IPC Classes  ?

• A61K 38/13 - Cyclosporins
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals

Abstract

In vitroin vitroin vitro method for the prediction of response to neoadjuvant chemotherapy (NAC), or for selecting a therapy, for triple negative breast cancer patients (TNBC). The method of the invention comprises determining the methylation status of the gene FERD3L and/or TRIP10 in a biological sample obtained from a patient, wherein a higher level of methylation of the gene FERD3L and/or TRIP10, as compared with the level of methylation of at least one of said genes in non-responder patients, is indicative of response to NAC in TNBC patients.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Goods & Services

Software platform for computers, social networks and mobile telephones, downloadable software. Internet platform access services.

Goods & Services

Downloadable software for the provision of telemedicine and for tracking, monitoring, reporting, and communicating patient vital signs, patient information and symptoms between patients and healthcare providers Internet platform access services, namely, internet service provider services in the nature of transmitting information via the Internet in the fields of telemedicine and telehealth

Goods & Services

(1) Computer software platforms for use in providing multiple user access to a global computer information network for social networking and via mobile telephones. (1) Providing access to the Internet.

Abstract

The invention relates to compounds for use in the prevention and/or treatment of immunological diseases, particularly rheumatoid arthritis systemic lupus erythematosus and lupus nephritis, characterized by the subcutaneous administration of isoforms of C4BP lacking the beta chain or polypeptides comprising the CCP6 region of the alpha chain of C4BP no more than once a week or at a dose ranging from 0.24 mg/m2 to 9.99 mg/m2. The invention also relates to pharmaceutical compositions comprising from 0.45 mg to 18.90 mg of said compounds for the prevention and/or treatment of said diseases.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention corresponds to the field of cancer and is related to predicting cancer detection, diagnosis, monitoring and prediction of response to treatment, in particular platelet derived-endothelial cell growth factor (PD-ECGF) levels for their use as a potential value in monitoring disease evolution and predicting response to anti-angiogenic treatment.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

Disclosed is an in vitro method to diagnose or determine the risk of developing a neurodegenerative disease in a subject based on the determination of the methylation pattern in certain regions of mitochondrial DNA from the subject or the determination of the nucleotide at the polymorphic position 16519 in the mitochondrial DNA of the subject. Also, disclosed are nucleic acids suitable for the in vitro method to diagnose or determine the risk of developing a neurodegenerative disease in a subject.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The invention relates to a recombinant adenovirus comprising an albumin-binding moiety on the outer surface of the adenoviral hexon protein, pharmaceutical compositions containing it and its medical use. Particularly, the invention relates to an oncolytic adenovirus comprising a sequence encoding an albumin-binding moiety inserted in the hypervariable region 1 (HVR1) of the hexon protein coding sequence and its use in the prevention and/or treatment of cancer.

IPC Classes  ?

• C07K 14/315 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• A61K 35/761 - Adenovirus
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C07K 14/075 - Adenoviridae
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

Abstract

It relates to a topical gel composition comprising lidocaine or its pharmaceutically acceptable salts and diclofenac or its pharmaceutically acceptable salts, together with one or more pharmaceutically acceptable excipients or carriers for use in the treatment of pre- and postoperative pain in the benign anorectal surgery by topical rectal administration using a specific dosage regime which consist of the administration twice per day during three days and once per day from the fourth day of treatment of the composition. It also relates to a specific topical lipogel composition especially suitable for this use as well as to a kit comprising the previous lipogel and a second pharmaceutical composition comprising lidocaine or a salt pharmaceutically acceptable thereof together with one or more pharmaceutically acceptable excipients or carriers.

IPC Classes  ?

• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Abstract

The present invention is directed to a diagnostic method for adrenoleukodystrophy in a subject based on the determination of the levels of different markers. The invention also provides a method for monitoring the progression of an adrenoleukodystrophy, a method for monitoring the effect of an adrenoleukodystrophy therapy and fingolimod, an analogue, metabolite or derivative thereof, or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prevention of anadrenoleukodystrophy.

IPC Classes  ?

• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups

Abstract

The present invention corresponds to the field of cancer and is related to predicting cancer detection, diagnosis,monitoring and prediction of response to treatment, in particular platelet derived-endothelial cell growth factor (PD-ECGF) levels for their use as a potential value in monitoring disease evolution and predicting response to anti-angiogenic treatment.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The invention relates to a method for the prognosis of hepatocellular carcinoma in an isolated sample of a subject, the method comprising providing a DNA methylation signature, said signature obtained from the qualitative and quantitative methylation analysis of 36 selected CpG sites. The invention also disclosesparticular methods in which a Mortality Index score is provided from said signature.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The invention relates to methods and reagents for the identification of the origin of a carcinoma of unknown primary origin (CUP) based on the determination of the methylation profile in the genome of the CUP. The invention relates as well to methods for selecting a suitable therapy for a patient suffering a CUP as well as to methods for personalized medicine of patient suffering a CUP based on the use of a treatment which is adequate for the primary tumor from which the CUP is derived. The invention also relates to kits comprising reagents adequate for performing the above methods as well as to computer systems and programs which can be used for implementing the methods of the invention.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The invention relates to a recombinant adenovirus comprising an albumin-binding moiety on the outer surface of the adenoviral hexon protein, pharmaceutical compositions containing it and its medical use. Particularly, the invention relates to an oncolytic adenovirus comprising a sequence encoding an albumin-binding moiety inserted in the hypervariable region 1 (HVRl) of the hexon protein coding sequence and its use in the prevention and/or treatment of cancer.

IPC Classes  ?

• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C07K 14/075 - Adenoviridae

Abstract

The invention relates to an in vitro method for diagnosing or determining the risk of a subject developing a neurodegenerative disease based on the determination of the methylation pattern in certain regions of the mitochondrial DNA of said subject or based on the determination of the nucleotide in the polymorphic position 16519 of the mitochondrial DNA of said subject. The invention further relates to nucleic acids suitable for implementing the invention.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

System for providing oxygen to a patient, comprising a sensing device (41) having an oxygen sensor (41) for obtaining one or more measurements of a level of oxygen in patient's blood, ari oxygen provider (45) for providing oxygen to the patient, and a control unit (40). The control unit (40) is configured to receive the level of oxygen in blood from the oxygen sensor (41), and to determine a parameter representative of oxygen insufficiency by comparing the level of oxygen in blood with an oxygen level threshold. The control unit (40) is further configured to determine an oxygen need depending at least on the parameter representative of oxygen insufficiency, and to cause the oxygen provider (45) to continuously provide the oxygen need to the patient until the oxygen need is determined to be substantially null.

IPC Classes  ?

• A61M 16/06 - Respiratory or anaesthetic masks
• A61M 16/00 - Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators Tracheal tubes

Abstract

The compounds of formula (I), or its pharmaceutically acceptable salts, or any stereoisomer or mixture thereof, wherein: R1 and R1' are both H, or R1 and R1' are taken together forming a biradical of formula -CH2-C(R4)=CH-; R2 and R3 are radical independently selected from the group consisting of H, F, CI and (C1-C4)-alkyl; R4 is a (C1-C2)-alkyl radical; and n is an integer from 2 to 15, are useful for the treatment of a neurodegenerative disorder such as Alzheimer's disease.

IPC Classes  ?

• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 219/10 - Nitrogen atoms attached in position 9
• C07D 221/18 - Ring systems of four or more rings

Abstract

The invention relates to methods and reagents for the treatment of immunological diseases. In particular, the invention relates to isoforms of the C4b-binding protein (C4BP) lacking beta chains as well as to fragments and peptides derived thereof and to the uses of these polypeptides for the treatment of immunological diseases such as immunoinflammatory disease, sepsis, an autoimmune disease, transplant rejection, graft-versus-host disease and a hypersensitivity disease. Moreover, the invention relates also the use of factor H for the treatment of immunological diseases. In addition, the invention relates to tolerogenic dendritic cells obtained using the C4BP isoform lacking beta chain, the peptides and fragments thereof and factor H and to the therapeutic uses of said cells.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C12N 5/0784 - Dendritic cellsProgenitors thereof
• A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
• A61K 35/36 - SkinHairNailsSebaceous glandsCerumenEpidermisEpithelial cellsKeratinocytesLangerhans cellsEctodermal cells

Abstract

Systems and methods for neuropathic pain treatment using neuromodulation are provided. In one embodiment, a wireless micro-neurostimulator is provided that is comprised of microelectrode(s) placed inside nerve(s) for neurostimulation, to treat peripheral neuropathic pain and other lesions related to the nerve. The micro-neurostimulator is implanted percutaneously and placed by ultrasound-guided puncture. It is recharged by induction charging, which allows recharging through the skin without wires penetrating the skin. Because the device is placed inside the nerve, however, the need for recharging is minimized. Advantageously, there is limited displacement of the micro-neurostimulator within the nerve due to muscle movement, and constant stimulus is provided because the device is moved with the nerve.

IPC Classes  ?

• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers

Abstract

The present invention relates to methods for determining the probability of transplant rejection based on the determination in the subject recipient of the transplant of the levels of antibodies specific for hyaluronic acid. The invention relates as well to methods for attenuating transplant rejection and compositions to prevent transplant rejection based on the depletion of anti- hyaluronic acid antibodies from the subject.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The invention relates to a box for protecting at least one connection used for the interconnection of catheters and/or drains and infusion and/or drainage equipment respectively, said box comprising a casing and characterised in that it comprises an element for projecting antiseptic liquid towards the connection, arranged inside the casing.

IPC Classes  ?

• A61M 39/16 - Tube connectors or tube couplings having provision for disinfection or sterilisation

Abstract

The invention relates to methods and reagents for the identification of the origin of a carcinoma of unknown primary origin (CUP) based on the determination of the methylation profile in the genome of the CUP. The invention relates as well to methods for selecting a suitable therapy for a patient suffering a CUP as well as to methods for personalized medicine of patiente suffering a CUP based on the use of a treatment which is adequate for the primary tumor from which the CUP is derived. The invention also relates to kits comprising reagents adequate for performing the above methods as well as to computer systems and programs which can be used for implementing the methods of the invention.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The invention relates to a method for generating a path for a virtual bronchoscopy, comprising generating a model of a tracheobronchial tree and a model of a bronchoscope. The model of the tracheobronchial tree comprises a representation of the walls of the tree and of a target zone. The model of the bronchoscope comprises a representation of a viewing end (tip) of the bronchoscope using a kinematic chain of inter-articulated rigid bodies. The rigid bodies include at least a base and a viewing body. The rotation of the articulations represents a tip bending movement. The method also comprises calculating a sequence of chain movements that moves the viewing body towards the target without any of the rigid bodies passing beyond the walls of the tracheobronchial tree, each segment being calculated by applying at least one chain articulation rotation value and a chain forward movement.

IPC Classes  ?

• G06F 19/12 - for modelling or simulation in systems biology, e.g. probabilistic or dynamic models, gene-regulatory networks, protein interaction networks or metabolic networks
• G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer
• G06T 17/10 - Volume description, e.g. cylinders, cubes or using CSG [Constructive Solid Geometry]

Abstract

The present invention is directed to pioglitazone, or a pharmaceutically acceptable salt thereof, as well as a pharmaceutical composition comprising pioglitazone, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, for use in the treatment and/or prevention of an adrenoleukodystrophy.

IPC Classes  ?

• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention relates to peptides derived from the RCAN proteins for their use in medicine and in the treatment of diseases in a subject occurring with uncontrolled cell proliferation, immune disorders, cardiovascular disorders, neurodegenerative diseases, alopecia, undesired angiogenesis and undesired PMN infiltration.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to mesenchymal stem cells (MSCs) that have been genetically modified to express ST2 or parts thereof for use in the treatment of pulmonary immunoinflammatory diseases, wherein said mesenchymal stem cells are not human embryo stem cells. The present invention also relates to pharmaceutical compositions that comprise said mesenchymal stem cells.

IPC Classes  ?

• C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells

Abstract

The present invention is related to methods for prevention and/or treatment of a number of diseases, such as lupus nephritis, ischemia/reperfusion injury and sepsis, based on the silencing of CD40 using different RNA silencing strategies.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides

Abstract

The invention is related to methods and compositions involving CD40 silencing by RNA interference and an immunosuppressive agent for preventing the rejection of kidney transplant in mammals and increasing tolerance in a recipient mammal to a kidney transplant.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides

Abstract

The invention relates to methods and reagents for the treatment of immunological diseases. In particular, the invention relates to isoforms of the C4b-binding protein (C4BP) lacking beta chains as well as to fragments and peptides derived thereof and to the uses of these polypeptides for the treatment of immunological diseases such as immunoinflammatory disease, sepsis, an autoimmune disease, transplant rejection, graft-versus-host disease and a hypersensitivity disease. Moreover, the invention relates also the use of factor H for the treatment of immunological diseases. In addition, the invention relates to tolerogenic dendritic cells obtained using the C4BP isoform lacking beta chain, the peptides and fragments thereof and factor H and to the therapeutic uses of said cells.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C12N 5/0784 - Dendritic cellsProgenitors thereof

Abstract

The present invention relates to the diagnosis and prognosis of metastasis in breast cancer based in the determination of the expression level of PRDX2gene. It also relates to a method for diagnosis and prognosis of metastasis in breast cancer based in the determination of the expression level of ERp57/GRP58gene. Lastly, the invention refers to the use of PRDX2and/or PRDX3 inhibitors and a ROS-generating agent for the treatment and/or prevention of lung metastasis in breast canceras well as to the use of ERp57/GRP58 inhibitors for the treatment and/or prevention of bone metastasis in breast cancers.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The invention is related to an oncolytic adenovirus that comprises a sequence encoding a hyaluronidase enzyme inserted in its genome. This adenovirus spreads more efficiently in the tumour mass and therefore the oncolytic effect is increased. Injecting the oncolytic adenovirus of the invention endovenously results in tumour volume regressions. Therefore, the oncolytic adenovirus of the present invention is useful for the treatment of a cancer or a pre-malignant state of cancer.

IPC Classes  ?

• C12N 15/861 - Adenoviral vectors
• C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
• C12N 15/60 - Lyases (4)
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• A61K 35/761 - Adenovirus
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12N 9/26 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on alpha-1, 4-glucosidic bonds, e.g. hyaluronidase, invertase, amylase
• C12N 15/86 - Viral vectors
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

The present invention is a combination of N-acetylcysteine (NAC) and alpha lipoic acid (LA), or pharmaceutically acceptable salts thereof, for the prevention and/or treatment of a disease with axonal damage and concomitant oxidative lesions in a mammal, in particular X-linked adrenoleukodystrophy (X-ALD). The mouse model of X-ALD shows a late- onset neurological phenotype of the disease of locomotor deficit and axonal degeneration as predominant pathologies characteristic of the disease. The inventors have found that treatment of mouse models of X-ALD with these two active principles achieves reversal of oxidative stress and of the derived lesions to proteins of the spinal marrow as target organ of the disease, on the one hand, moreover however achieving prevention and reversal of axonal degeneration and furthermore correcting locomotor deficit presented by the mouse model of the disease, that is to say, the clinical symptomatology thereof.

IPC Classes  ?

• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/385 - Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia